MX2022011101A - Formulaciones de anticuerpos anti protofibrillas beta amiloide de alta concentracion y metodos de uso de las mismas. - Google Patents
Formulaciones de anticuerpos anti protofibrillas beta amiloide de alta concentracion y metodos de uso de las mismas.Info
- Publication number
- MX2022011101A MX2022011101A MX2022011101A MX2022011101A MX2022011101A MX 2022011101 A MX2022011101 A MX 2022011101A MX 2022011101 A MX2022011101 A MX 2022011101A MX 2022011101 A MX2022011101 A MX 2022011101A MX 2022011101 A MX2022011101 A MX 2022011101A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- high concentration
- protofibril antibody
- antibody formulations
- concentration anti
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
En el presente documento se proporcionan formulaciones farmacéuticas acuosas que comprenden altas concentraciones de un anticuerpo anti protofibrillas Aß aislado o un fragmento del mismo que se une a protofibrillas Aß humanas, tal como BAN2401, arginina, polisorbato 80 y un amortiguador farmacéuticamente aceptable.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992746P | 2020-03-20 | 2020-03-20 | |
| US202063027263P | 2020-05-19 | 2020-05-19 | |
| PCT/IB2021/000155 WO2021186245A1 (en) | 2020-03-20 | 2021-03-19 | HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011101A true MX2022011101A (es) | 2022-10-03 |
Family
ID=75746958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011101A MX2022011101A (es) | 2020-03-20 | 2021-03-19 | Formulaciones de anticuerpos anti protofibrillas beta amiloide de alta concentracion y metodos de uso de las mismas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230183328A1 (es) |
| EP (2) | EP4252777A3 (es) |
| JP (1) | JP2023518066A (es) |
| KR (1) | KR20220156534A (es) |
| CN (1) | CN115315251A (es) |
| AU (1) | AU2021238951A1 (es) |
| BR (1) | BR112022018766A2 (es) |
| CA (1) | CA3174778A1 (es) |
| CL (1) | CL2022002517A1 (es) |
| CO (1) | CO2022012916A2 (es) |
| IL (1) | IL295383A (es) |
| MX (1) | MX2022011101A (es) |
| TW (1) | TW202200201A (es) |
| WO (1) | WO2021186245A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| WO2023283650A1 (en) | 2021-07-09 | 2023-01-12 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| TW202339794A (zh) | 2022-02-02 | 2023-10-16 | 日商衛材R&D企管股份有限公司 | 使用ｐ—ｔａｕ１８１水平之治療方法 |
| WO2024118665A1 (en) | 2022-11-28 | 2024-06-06 | Eisai R&D Management Co., Ltd. | Methods of treatment using a tau pet level |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112805031A (zh) * | 2018-07-24 | 2021-05-14 | 卫材R&D管理有限公司 | 阿尔茨海默病的治疗及预防方法 |
-
2021
- 2021-03-19 CN CN202180019180.6A patent/CN115315251A/zh active Pending
- 2021-03-19 CA CA3174778A patent/CA3174778A1/en active Pending
- 2021-03-19 JP JP2022556091A patent/JP2023518066A/ja active Pending
- 2021-03-19 KR KR1020227030919A patent/KR20220156534A/ko unknown
- 2021-03-19 IL IL295383A patent/IL295383A/en unknown
- 2021-03-19 US US17/906,660 patent/US20230183328A1/en active Pending
- 2021-03-19 EP EP23179487.6A patent/EP4252777A3/en active Pending
- 2021-03-19 MX MX2022011101A patent/MX2022011101A/es unknown
- 2021-03-19 WO PCT/IB2021/000155 patent/WO2021186245A1/en active Application Filing
- 2021-03-19 EP EP21722538.2A patent/EP4121007A1/en active Pending
- 2021-03-19 BR BR112022018766A patent/BR112022018766A2/pt unknown
- 2021-03-19 AU AU2021238951A patent/AU2021238951A1/en active Pending
- 2021-03-22 TW TW110110263A patent/TW202200201A/zh unknown
-
2022
- 2022-09-12 CO CONC2022/0012916A patent/CO2022012916A2/es unknown
- 2022-09-14 CL CL2022002517A patent/CL2022002517A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202200201A (zh) | 2022-01-01 |
| CL2022002517A1 (es) | 2023-03-24 |
| EP4252777A3 (en) | 2024-01-24 |
| JP2023518066A (ja) | 2023-04-27 |
| KR20220156534A (ko) | 2022-11-25 |
| CO2022012916A2 (es) | 2022-09-20 |
| EP4252777A9 (en) | 2024-03-06 |
| BR112022018766A2 (pt) | 2022-11-01 |
| CA3174778A1 (en) | 2021-09-23 |
| IL295383A (en) | 2022-10-01 |
| CN115315251A (zh) | 2022-11-08 |
| US20230183328A1 (en) | 2023-06-15 |
| EP4252777A2 (en) | 2023-10-04 |
| WO2021186245A1 (en) | 2021-09-23 |
| AU2021238951A1 (en) | 2022-10-20 |
| EP4121007A1 (en) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011101A (es) | Formulaciones de anticuerpos anti protofibrillas beta amiloide de alta concentracion y metodos de uso de las mismas. | |
| CY1123667T1 (el) | Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου | |
| CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| WO2020126620A3 (en) | Improved antibody-oligonucleotide conjugate | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| CY1114185T1 (el) | Υποδοριο σκευασμα αντισωματος αντι-her2 | |
| MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
| PL373001A1 (en) | Combination of azelastine and steroids | |
| CY1112082T1 (el) | Υγρη φαρμακοτεχνικη μορφη fsh | |
| CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
| BR112022016456A2 (pt) | Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos | |
| EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| MX2023004032A (es) | Terapias inmuno-oncologicas con conjugados de il-2. | |
| MX2021009851A (es) | Formulacion de anticuerpos terapeuticos. | |
| MX2021012782A (es) | El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion. | |
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| MX2023009971A (es) | Composicion farmaceutica que contiene anticuerpo anti-tslp. | |
| MX2022011651A (es) | Composicion farmaceutica para tratamiento de diabetes. | |
| WO2023009759A3 (en) | Antibody-drug conjugates and methods of use thereof | |
| WO2019087133A8 (en) | Method of treating tendinopathy using interleukin-17 (il-17) antagonists | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2022015769A (es) | Tubulisinas y conjugados de proteina-tubulisina. |